Supplementary Materials

Supplementary Materials for:

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs

Heather Torrey, John Butterworth, Toshiyuki Mera, Yoshiaki Okubo, Limei Wang, Danielle Baum, Audrey Defusco, Sara Plager, Sarah Warden, Daniel Huang, Eva Vanamee, Rosemary Foster, Denise L. Faustman*

*Corresponding author. Email: faustman{at}helix.mgh.harvard.edu

This PDF file includes:

  • Fig. S1. TNFR2 antagonists inhibit Treg proliferation in the presence of IL-2 and TNF.
  • Fig. S2. TNFR2 antagonists inhibit Treg expansion by TNF.
  • Fig. S3. Functional activity of TNFR2 antagonists is independent of Fc region or receptor cross-linking.
  • Fig. S4. Inhibition of cell division limits the efficacy of TNFR2 antagonist inhibition of Tregs.
  • Fig. S5. Representative FACS dot plot of OVCAR3 live/dead staining analysis and TNFR2 oncogene abundance.
  • Fig. S6. Treatment of CD4+ cells with TNFR2 antagonistic antibodies reduces NF- κB activation.

[Download PDF]

Technical Details

Format: Adobe Acrobat PDF

Size: 800 KB


Citation: H. Torrey, J. Butterworth, T. Mera, Y. Okubo, L. Wang, D. Baum, A. Defusco, S. Plager, S. Warden, D. Huang, E. Vanamee, R. Foster, D. L. Faustman, Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci. Signal. 10, eaaf8608 (2017).

© 2017 American Association for the Advancement of Science